197
Views
13
CrossRef citations to date
0
Altmetric
Retina and Optic Nerve

LncRNA NKILA Inhibits Retinoblastoma by Downregulating lncRNA XIST

, , , &
Pages 975-979 | Received 25 Dec 2018, Accepted 03 Apr 2019, Published online: 15 May 2019
 

ABSTRACT

Purpose

Although retinoblastoma is rare but can be deadly in some severe cases. To find novel therapeutic targets for retinoblastoma, we explored the potential role of lncRNA NKILA in retinoblastoma.

Results

We found that, comparing to healthy controls, NKILA was downregulated, while lncRNA XIST was upregulated in plasma of retinoblastoma patients and they were inversely correlated. Downregulation of NKILA distinguished early-stage patients from healthy controls. Overexpression of lncRNA NKILA mediated the downregulation of XIST in retinoblastoma cells, while XIST overexpression failed to significantly affect NKILA. Overexpression of NKILA resulted in decreased, while XIST overexpression resulted in increased proliferation, migration and invasion rates of retinoblastoma cells. In addition, rescue experiment showed that XIST overexpression attenuated the effects of NKILA overexpression on cancer cell behaviors.

Conclusions

Therefore, NKILA inhibits retinoblastoma possibly by downregulating XIST, but the causality has not been fully validated.

Disclosure Statement

The authors declare that they have no conflict of interests.

Additional information

Funding

Not applicable.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.